China News Service, March 12 (Reporter Chen Jing) Breast cancer is the number one malignant tumor that seriously threatens the health of women in the world.
Although early-stage breast cancer has become a curable disease, there are still 30%-40% of patients with advanced disease.
The reporter learned on the 12th that China's National Medical Products Administration (NMPA) officially approved China's original research drug-Uti Di?
(Common name: Uti Delong) is used for the treatment of recurrent and metastatic advanced breast cancer.
As an epothilone anti-tumor drug, the approval of Tidelon has broken the “bottleneck” in the treatment of advanced breast cancer in China for a long time, and ended the situation that China had no breakthrough chemotherapy drugs other than paclitaxel in the past three decades.
It is reported that, thanks to the national policy of encouraging the creation of new drugs and accelerating review and approval, Utidelon was listed as a national class I anti-tumor innovative drug and won the national "13th Five-Year Plan" major new drug creation project.
It is understood that for patients with advanced breast cancer, prolonging their survival period and improving their quality of life are the main treatment goals.
In recent years, breakthroughs have been made in targeted therapy and immunotherapy, but chemotherapy is still the basic treatment for advanced breast cancer.
It is reported that paclitaxel and anthracyclines are the main chemotherapy for breast cancer at this stage, but most patients with metastatic breast cancer have used paclitaxel and anthracyclines in the early stage, which is prone to drug resistance and cumulative toxicity. , Severe hematological toxicity and hair loss and other adverse reactions have brought risks and psychological trauma to patients with advanced breast cancer, greatly affecting their compliance and overall treatment benefits.
Professor Xu Binghe from the Cancer Hospital of the Chinese Academy of Medical Sciences bluntly said in an interview with a reporter from Chinanews.com that the treatment of advanced breast cancer is more complicated, and patients generally face problems such as short survival and poor quality of life.
Utidrolone can significantly improve the progression-free survival of patients with advanced breast cancer, reduce the risk of disease progression and death, and has no obvious liver toxicity and gastrointestinal toxicity caused by general chemotherapy drugs.
The results of a prospective, multi-center phase III clinical study showed that compared with capecitabine alone, for advanced breast cancer patients who have previously used anthracyclines and taxanes, they received Utidrolone combined with capecita The overall survival period of the patients treated with steroids was significantly extended from 15.7 months to 20.9 months, and the risk of death was reduced by 31%; the progression-free survival period of patients was significantly extended from 4.11 months to 8.57 months, and the risk of disease progression was reduced by 54%; the remission rate was reduced from 26.7% increased to 49.8%, a significant increase of nearly double.
This curative effect is a new breakthrough in the field of breast cancer chemotherapy in the past 30 years.
The company revealed that it will continue to deepen the development of various new indications of UTI Delong, while accelerating the development of different dosage forms, using independent key technology platforms to promote the follow-up research and development of other innovative drugs with different targets, and plans to develop local research and development. Of innovative drugs to the international market. (Finish)